Non-steroidal anti-inflammatory drug gastropathy and Helicobacter pylori infection.
The interest in the interaction between NSAIDs and Helicobacter pylori derives its importance from its potential to provide a different strategy to combat the common problem of NSAID-related peptic ulcers and their life threatening complications. Studies assessing this subject have differed in almost every aspect of their methodology, including the definition of a NSAID user as well as the types, doses, duration, and the indications for NSAID use. They also differed in their end points, the tests for the assessment of Helicobacter pylori, and the regimes used for its eradication. However, NSAIDs and Helicobacter pylori are known to share a number of important pathogenic mechanisms, and the prevalence of the infection is high in cohorts of ulcer patients taking NSAIDs. Eradication of Helicobacter pylori using bismuth-based regimes has also been more successful and beneficial in preventing the occurrence or relapse of NSAID-related ulcers than regimes using proton pump inhibitors.
Taha
A S
AS
Department of Gastroenterology, Crosshouse Hospital, Kilmarnock, Scotland, UK.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D005260:Female; D005756:Gastritis / Q000453:epidemiology / Q000209:etiology*; D016481:Helicobacter Infections / Q000139:chemically induced* / Q000175:diagnosis; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D015994:Incidence; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D013276:Stomach Ulcer / Q000139:chemically induced / Q000453:epidemiology / Q000382:microbiology*
D000894:Anti-Inflammatory Agents, Non-Steroidal